Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine in resected pancreatic adenocarcinoma
2013-003398-91Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing nab-paclitaxel + gemcitabine with gemcitabine alone (2 arms). Primary endpoint: Disease-free survival. Started Mar 2014; status: completed.
02
Drugs
paclitaxelgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2013-003398-91.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003398-91.